Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.
Petrarca
Antonio
A
Center for Systemic Manifestations of Hepatitis Viruses (MaSVE), Department of Internal Medicine, University of Florence, Florence, Italy.
Rigacci
Luigi
L
Caini
Patrizio
P
Colagrande
Stefano
S
Romagnoli
Paolo
P
Vizzutti
Francesco
F
Arena
Umberto
U
Giannini
Carlo
C
Monti
Monica
M
Montalto
Paolo
P
Matucci-Cerinic
Marco
M
Bosi
Alberto
A
Laffi
Giacomo
G
Zignego
Anna Linda
AL
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes / Q000276:immunology; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012157:Mononuclear Phagocyte System / Q000473:pathology; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D012367:RNA, Viral; D000069283:Rituximab